Core Viewpoint - Junyao Health is a well-known company in the domestic lactic acid beverage sector, focusing on the research, production, and sales of high-quality lactic acid drinks, with advanced production processes and strict quality control systems [1] Group 1: Business Performance - In Q3 2025, Junyao Health reported revenue of 1.095 billion yuan, ranking 12th in the industry, significantly lower than the top player Yili Group at 90.341 billion yuan and second-place Bright Dairy at 18.231 billion yuan [2] - The main business composition includes probiotic beverages at 261 million yuan (34.11%), supply chain products at 261 million yuan (34.07%), probiotic foods at 168 million yuan (21.98%), and other beverages and foods at 73.183 million yuan (9.55%) [2] - The net profit for the same period was -11.3712 million yuan, ranking 14th in the industry, with a notable gap compared to Yili Group's net profit of 10.42 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Junyao Health's debt-to-asset ratio was 15.81%, lower than the previous year's 16.89% and significantly below the industry average of 41.11%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 31.18%, an increase from 29.81% in the previous year and higher than the industry average of 24.79% [3] Group 3: Executive Compensation - The chairman, Wang Junhao, received a salary of 3.1266 million yuan in 2024, a decrease of 78,100 yuan from 2023 [4] - The general manager, Yu Wei, earned a salary of 1.9935 million yuan in 2024 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 19.52% to 34,300, while the average number of circulating A-shares held per household increased by 24.25% to 17,500 [5] - Tianhong Zhongzheng Food and Beverage ETF ranked as the tenth largest circulating shareholder, holding 948,500 shares, an increase of 116,700 shares from the previous period [5]

Core Insights - Junyao Health is experiencing ongoing performance challenges during its transformation, with a decline in both revenue and net profit reported for Q3 2025 [1][2] - The company has faced a continuous drop in net profit for five consecutive years, with a reported loss of 29.12 million yuan last year [1][2] - Despite a significant increase in revenue from probiotic products, overall revenue has decreased, and the company continues to invest heavily in sales, marketing, and R&D, making it difficult to alleviate performance declines in the short term [1][3] Financial Performance - For the first three quarters of 2025, Junyao Health reported approximately 1.095 billion yuan in revenue, a year-on-year decrease of 6.95% [2] - The net profit attributable to shareholders was a loss of approximately 2.3688 million yuan, a year-on-year decline of 104.79% [2] - In Q3 alone, revenue was about 329 million yuan, down 21.9% year-on-year, with a net profit loss of approximately 9.8349 million yuan, a decline of 167.09% [2] Business Challenges - The decline in performance is attributed to reduced income and increased expenditures, leading to a decrease in total profit from the beginning of the year to the reporting period [3] - Revenue from probiotic beverages decreased by 21.35% year-on-year to 386 million yuan, with declines observed across all major regions [3] - The company faces pressure from a challenging consumer environment, a shrinking market share in the dairy beverage sector, and weak downstream customer demand [3] Strategic Initiatives - Junyao Health is focusing on optimizing its revenue structure, with new product lines showing rapid development, although this has led to increased upfront sales and marketing costs [3][5] - The company has expanded its functional strain resource library to over 50,000 strains and successfully developed low-temperature probiotic beverages [3][5] - The overseas business has seen a significant growth of 72.20% compared to the same period last year, with products now available in over 80 countries and regions [3] Market Trends - The domestic beverage market is facing challenges due to the rapid growth of freshly made tea drinks, which are replacing standardized products like dairy and probiotic beverages [4] - The decline in the probiotic beverage market is also linked to changing consumer health preferences and the fragmentation of distribution channels [4] - The international market presents a key growth opportunity for Junyao Health, particularly for probiotic beverages, although rapid growth does not guarantee profitability [4] Product Development - Junyao Health has launched new probiotic products, including low-temperature active probiotic beverages, which are positioned to enhance overall profit margins [6][7] - The company aims to leverage its probiotic business to support future beverage operations, although challenges such as high cold chain costs and inventory management remain [6][7]

Market Overview - The beverage and dairy sector experienced a decline of 0.54% on the trading day, with Junyao Health leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Stock Performance - Notable gainers in the beverage and dairy sector included: - Weiweijia (600300) with a closing price of 3.47, up 2.97% [1] - New Dairy (002946) at 17.01, up 2.47% [1] - Yili (600887) at 27.36, up 0.66% with a transaction volume of 621,200 shares and a transaction value of 1.702 billion [1] - Major decliners included: - Junyao Health (605388) at 7.13, down 3.52% [2] - Happy Home (300997) at 16.62, down 3.26% [2] - Beiyinmei (002570) at 6.28, down 2.64% with a transaction value of 305 million [2] Capital Flow - The beverage and dairy sector saw a net inflow of 193 million from institutional investors, while retail investors experienced a net outflow of 39.39 million [2] - The capital flow for key stocks showed: - Yili (600887) had a net inflow of 285 million from institutional investors, but a net outflow of 172 million from retail investors [3] - Chengde Lululemon (000848) had a net inflow of 42.62 million from institutional investors, with a net outflow of 5.37 million from retail investors [3] - Miao Ke Lan Duo (600882) had a net inflow of 20.36 million from institutional investors, but a significant net outflow of 29.61 million from retail investors [3]

Core Insights - Junyao Health reported a revenue of approximately 329 million yuan for Q3 2025, representing a year-on-year decrease of 21.91% [1] - The company recorded a net loss attributable to shareholders of approximately 18.54 million yuan, which is a year-on-year increase in loss of 213.62% [1]

Group 1 - The core viewpoint of the article is that Junyao Health (605388.SH) reported a significant decline in revenue and net profit for the third quarter of 2025 [1] Group 2 - The company's operating revenue for the third quarter was 329 million yuan, representing a year-on-year decrease of 21.91% [1] - The net profit attributable to shareholders of the listed company was -9.83 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -13.20 million yuan [1]

证券代码：605388 证券简称：均瑶健康 公告编号：2025-058 湖北均瑶大健康饮品股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 10 月 29 日 (二)股东会召开的地点：上海市浦东新区康桥东路 2 弄 1 号楼大会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 314 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 407,692,620 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 69.5930 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由湖北均瑶大健康饮品股份有限公司（以下简称"公司"）董事 会召集，本次会议现场由董事长王均豪先生主持，采用现场与网络投 ...

北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN H O N G K O N G PARIS MADRID S I L I C O N V A L L E Y 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 52433320 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于湖北均瑶大健康饮品股份有限公司 2025 年第三次临时股东会 法律意见书 致：湖北均瑶大健康饮品股份有限公司 根据《中华人民共和国公司法》（以下 ...

Group 1 - The core viewpoint of the news is that Junyao Health reported a decline in revenue and a net loss for the third quarter of 2025, indicating potential challenges for the company [1] - For the first three quarters of 2025, Junyao Health's revenue was approximately 1.095 billion yuan, representing a year-on-year decrease of 6.95% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 2.37 million yuan [1] Group 2 - As of the time of reporting, Junyao Health's market capitalization was 4.4 billion yuan [2]

Financial Performance - Total revenue for Q3 2025 was CNY 328,718,538.30, a decrease of 21.91% compared to the same period last year[4] - The total profit for the period was a loss of CNY 18,544,505.93, representing a decline of 213.62% year-on-year[4] - Net profit attributable to shareholders was a loss of CNY 9,834,901.33, down 167.09% from the previous year[4] - The basic earnings per share for the period was -CNY 0.0164, a decrease of 166.40% compared to the same period last year[5] - The company experienced a 365.11% decline in net profit after deducting non-recurring gains, totaling a loss of CNY 13,203,863.10 for the period[4] - Net profit attributable to shareholders for the current reporting period decreased to -167.09 million RMB, reflecting a significant drop in total profit[10] - Basic and diluted earnings per share for the current reporting period were both -166.3968 RMB, indicating a decline due to reduced total profit[10] - Net profit for the first three quarters of 2025 was a loss of CNY 11,371,197.00, compared to a profit of CNY 47,039,358.08 in 2024[28] - The company's operating profit for the first three quarters of 2025 was a loss of CNY 15,427,359.49, down from a profit of CNY 64,980,494.86 in the same period of 2024[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,017,573,820.66, a decrease of 12.79% from the end of the previous year[5] - The total liabilities decreased to CNY 319,056,799.83 in 2025 from CNY 548,716,746.59 in 2024, a reduction of 41.8%[24] - The total assets decreased to CNY 2,017,573,820.66 in 2025 from CNY 2,313,498,343.10 in 2024, a decline of 12.7%[24] - The company's equity attributable to shareholders decreased to CNY 1,715,649,397.36 in 2025 from CNY 1,772,911,604.62 in 2024, a decrease of 3.2%[24] Cash Flow - The cash flow from operating activities for the year-to-date was -CNY 87,189,611.93[4] - Cash inflow from sales of goods and services for the first three quarters of 2025 was $1,125,447,051.37, an increase of 5.76% compared to $1,064,200,690.63 in the same period of 2024[30] - Net cash flow from operating activities for the first three quarters of 2025 was -$87,189,611.93, compared to -$77,301,998.80 in 2024, indicating a decline in operational cash flow[30] - Total cash inflow from investment activities in the first three quarters of 2025 was $117,867,191.27, down from $172,694,409.60 in 2024, reflecting a decrease of 31.73%[31] - Net cash flow from investment activities improved to $48,856,444.18 in 2025, compared to -$106,178,718.47 in 2024, showing a significant recovery[31] - Cash inflow from financing activities totaled $48,153,848.80 in 2025, compared to $16,330,000.00 in 2024, marking a substantial increase of 194.56%[31] - The net cash flow from financing activities was -$52,088,707.44 in 2025, an improvement from -$87,380,733.01 in 2024[31] - The ending cash and cash equivalents balance for the first three quarters of 2025 was $135,448,848.48, down from $189,092,090.84 in 2024[31] Business Operations - The company reported a significant decline in probiotic beverage business revenue due to ongoing consumer demand pressures and market share loss in the dairy beverage sector[9] - The company's probiotic beverage revenue declined, leading to a year-on-year profit decrease of 213.62%[10] - The company is optimizing its revenue structure, with new product lines developing rapidly despite increased sales and marketing expenses[10] - The company’s overall operations showed resilience, with a commitment to technological innovation and quality improvement[14] - The company's probiotic food revenue reached 228 million RMB in the first three quarters of 2025, representing a year-on-year growth of 60.32%[15] - Online business saw a significant increase, with e-commerce sales growing by 120.84% compared to the same period last year[15] - The overseas channel business grew by 72.20% year-on-year, with products now covering over 80 countries and regions globally[15] - The probiotic business, as a core growth driver, achieved a revenue increase of 33.29% year-on-year[17] - The U.S. market showed strong performance, contributing nearly half of the overseas revenue, with significant order increases from key clients[19] - The company has successfully entered the pharmacy sector with its probiotic products, marking a new breakthrough in terminal coverage[21] Research and Development - The company increased R&D expenses, expanding its functional strain resource library to 50,000 strains, and launched a low-temperature probiotic beverage[10] - Research and development investment reached 28.41 million RMB in the first three quarters of 2025, marking a 20% increase compared to the previous year[17] - The company established a proprietary strain library of over 50,000 strains and created a "Six-Diamond" selection standard for quality benchmarks[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,338, with no preferred shareholders recovering voting rights[12] - The largest shareholder, Shanghai Junyao Group, holds 196,632,002 shares, representing 32.75% of the total shares[13] Accounting Standards - The company will not apply new accounting standards starting from 2025, as stated in the announcement[32]

证券代码：605388 证券简称：均瑶健康 公告编号：2025-059 湖北均瑶大健康饮品股份有限公司 2025 年前三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十二 号——酒制造》的相关规定，现将湖北均瑶大健康饮品股份有限公司（以下简称 "公司"）2025 年前三季度主要经营数据（未经审计）公告如下： 一、公司 2025 年前三季度主要经营情况： | 区域 | 2025 | 年1-9月主营业 务收入 | 2024 年 | 1-9 月主营业 务收入 | 变动比例 | | --- | --- | --- | --- | --- | --- | | 电商 | | 115,550,449.24 | | 52,323,513.26 | 120.84% | | 华东 | | 644,565,202.60 | | 779,495,163.25 | -17.31% | | 华中 | | 90,321,835.51 | | 133,941,308.1 ...